Press releaseGlobe Newswire
Amicus Therapeutics
FOLD · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- NewsErica Kollmann
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
- News
Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate
- Press releaseGlobe Newswire
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS
- Press releaseBusiness Wire
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
- Press releasePRNewswire
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--EKSO, FOLD, CWAN, and JHG
- Press releasePRNewswire
Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights
- Press releaseBusiness Wire
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
- Press releasePRNewswire
Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights
- NewsAvi Kapoor
Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results
- NewsAvi Kapoor
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
- Press releasePRNewswire
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
- Press releaseGlobe Newswire
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
- Press releaseBusiness Wire
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
- News
BioMarin To Acquire Amicus For $14.50/Shr In All-Cash Transaction For Total Equity Value Of ~$4.8B
- Press releasePRNewswire
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
- Press releaseGlobe Newswire
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
- News
Amicus Therapeutics Q3 Adj. EPS $0.17 Beats $0.04 Estimate, Sales $169.061M Beat $165.706M Estimate
- Press releaseGlobe Newswire
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
- News
Earnings Scheduled For November 4, 2025
- NewsAvi Kapoor
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- Press releasePRNewswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
- News
Amicus Therapeutics Q2 Adj. EPS $0.01 Beats $(0.11) Estimate, Sales $154.688M Beat $147.399M Estimate
- Press releaseGlobe Newswire
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
- Press releasePRNewswire
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
- Press releaseGlobe Newswire
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
- News
Amicus Therapeutics Earnings Preview
- Press releaseBusiness Wire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
- Press releaseGlobe Newswire
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
- Press releaseGlobe Newswire
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
- Press releaseGlobe Newswire
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
- NewsVandana Singh
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
- NewsAvi Kapoor
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.